![CATZ study showed adding zonisamide to existing medications reduced frequency of seizures in children aged 6-17 years.[© ktsdesign - Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/Aug31_2011_7427959_BrainwithLightning_PosResultsEisaiPediatricEpilepsyDrug2437321111-218x150.jpg "New Optogenetic Tool May Find Application in Understanding Epileptic Seizures")
AGTC CEO Sue Washer told GEN the change will not hurt the development program, despite the start of the trial being pushed back a few months from AGTC’s earlier estimate of a planned launch by the end of 2020 . . .
AGTC Sets Sights on Late-Stage Retinitis Pigmentosa Gene Therapy Trial
In a three-way race to develop a gene therapy for X-linked RP, AGTC CEO Sue Washer says trial inception delay won’t hurt the development program.
Applied Genetic Technologies Corp. (AGTC) says it will launch its planned Phase II/III trial of its gene therapy candidate for X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene, in the first quarter of 2021 [AGTC]
